Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Zymeworks Inc ZYME

Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based therapeutic candidates. Its platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. Its pipeline includes four preclinical candidates: ZW191, ZW171, ZW220, and ZW251.


NDAQ:ZYME - Post by User

Comment by Gringottson Nov 09, 2021 6:30pm
129 Views
Post# 34107278

RE:what's not to like about ZYME ?

RE:what's not to like about ZYME ?

It is heartening to know someone is reading and posting on the Zyme billboard.

By the way, I agree. The vast majority of shares are owned by investment companies.  

The share price slide from the high $50's earlier this year was unnerving. 

My fear is the company will be bought out for next to nothing. Hostile or through an offer. 

If an offer of $44 were made today ( 100% above today's closing price) I fear it could be accepted. I believe the company is well worth over $100, perhaps closer $200.

I hope today's conference regarding bringing product to market is meaningful. 

Ironically, Zyme was offered $50 a share in July this year, and little or nothing came from it. There wasn't a peep from the company. $50 though is better than $44. Lol.

GLTA

<< Previous
Bullboard Posts
Next >>